

Sanofi  
Form 6-K  
July 25, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July 2012

Commission File Number: 001-31368

**SANOFI**

(Translation of registrant's name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

## Edgar Filing: Sanofi - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

## Edgar Filing: Sanofi - Form 6-K

---

In July 2012, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.3 which are incorporated herein by reference.

### Exhibit List

Exhibit	
No.	Description
Exhibit 99.1	Press release dated June 22, 2012: Sanofi Pasteur's 6-in-1 Pediatric Vaccine Hexaxim Receives Positive Opinion from European Medicines Agency
Exhibit 99.2	Press release dated July 20, 2012: Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program with LDL Cholesterol-Lowering PCSK9 Antibody
Exhibit 99.3	Press release dated July 25, 2012: Sanofi Pasteur's Dengue Vaccine Demonstrates Proof of Efficacy

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 25, 2012

SANOFI

By /S/ John Felitti  
Name: John Felitti  
Title: Associate Vice President,  
Corporate Law, Financial & Securities Law

**Exhibit Index**

Exhibit	
No.	Description
Exhibit 99.1	Press release dated June 22, 2012: Sanofi Pasteur s 6-in-1 Pediatric Vaccine Hexaxim Receives Positive Opinion from European Medicines Agency
Exhibit 99.2	Press release dated July 20, 2012: Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program with LDL Cholesterol-Lowering PCSK9 Antibody
Exhibit 99.3	Press release dated July 25, 2012: Sanofi Pasteur s Dengue Vaccine Demonstrates Proof of Efficacy